TheEdgeResearch
Home / Stocks / FMS

Fresenius Medical Care AG & Co. KGaA (FMS)

NYSE Healthcare Medical - Care Facilities
$22.69 ▲ +1.52%
Market Cap
$12.19B
Sector
Healthcare
Industry
Medical - Care Facilities
Beta
0.74
52-Wk Range
20.02-27.64
CEO
Helen Giza
Country
DE
Currency
USD

Fresenius Medical Care AG & Co. KGaA operates in the Medical - Care Facilities industry of the Healthcare sector, headquartered in Bad Homburg, HE, DE. The stock last traded at $22.69, up 1.52% on the session, giving a market capitalisation of $12.19B. On trailing twelve-month figures it carries a trailing P/E of 11.99, a net margin of 4.8%. Its beta of 0.74 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
11.99
Price / Sales
0.55
Price / Book
0.85
EV / EBITDA
5.81
Gross margin
26.4%
Operating margin
10.7%
Net margin
4.8%
Return on equity
—
Debt / equity
0.87
Current ratio
1.07
Dividend yield
3.7%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange
Employees
108,165
IPO date
1996-09-17
Headquarters
Bad Homburg, HE, DE
About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Comparable companies

Fresenius Medical Care AG & Co. KGaA is most often compared with the following Healthcare names:

DVAEHCHOLXICLRRPRXSNNSOLVTEMTHCUHS
More research on FMS
FMS technical analysis FMS TheEdge Score Compare against peers
Open full interactive analysis & DCF →